Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06159920
Status:
RECRUITING
Last Update Posted:
2024-03-06
First Post:
2023-11-27
Brief Title:
Evaluation of the Diagnostic and Prognostic Role of PET PETCT and PETMRI in Neuroendocrin Tumors
Sponsor:
IRCCS San Raffaele
Organization:
IRCCS San Raffaele
Study Overview
Official Title:
Evaluation of the Diagnostic and Prognostic Role of PET PETCT and PETMRI in Neuroendocrin Tumors
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neuroendocrine tumors NETs constitute approximately 05 of malignancies To date diagnosis at an increasingly early stage of the disease is possible thanks to recent technological advances in biomedical imaging In particular the traditional work-up for these pathologies includes endoscopy magnetic resonance imaging MRI and computed tomography CT Furthermore the integrated positron emission tomography methods PETCT and PETMRI are innovative molecular imaging techniques and represent a continually expanding field of research in the oncology setting In particular PET is taking on an increasingly relevant role for the study of neuroendocrine tumors also thanks to the introduction of increasingly accurate radiopharmaceuticals targeted towards somatostatin receptors thus opening the way to new possibilities for the diagnosis andcharacterization of these tumors is in the staging and restaging phase
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None